Ekso Bionics Holdings, Inc. (EKSO) News
Filter EKSO News Items
EKSO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest EKSO News From Around the Web
Below are the latest news stories about EKSO BIONICS HOLDINGS INC that investors may wish to consider to help them evaluate EKSO as an investment opportunity.
Ekso Bionics to Showcase Its Device Technology in ‘AI for Good’ Webinar on Tuesday, November 19SAN RAFAEL, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Katherine Strausser, Principal Controls Engineer at Ekso Bionics, will be participating in an ‘AI for Good’ webinar. The webinar, entitled “AI-powered Exoskeletons Revolutionizing Rehabilitation and Mobility”, will take place on Tuesday, November 19 at 10:00 a.m. ET. The session will exp |
Ekso Bionics to Participate at the 15th Annual Craig-Hallum Alpha Select ConferenceSAN RAFAEL, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, Chief Executive Officer, and Jerome Wong, Chief Financial Officer, will be participating at the 15th Annual Craig-Hallum Alpha Select Conference taking place in New York on Tuesday, November 19, 2024. Management will be participating in one-on-one meetings with institutional |
Ekso Bionics Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagEkso Bionics Holdings ( NASDAQ:EKSO ) Third Quarter 2024 Results Key Financial Results Revenue: US$4.13m (down 10% from... |
Q3 2024 Ekso Bionics Holdings Inc Earnings CallQ3 2024 Ekso Bionics Holdings Inc Earnings Call |
Ekso Bionics Holdings Inc (EKSO) Q3 2024 Earnings Call Highlights: Navigating Challenges with ...Despite a dip in quarterly sales, Ekso Bionics Holdings Inc (EKSO) improves margins and strengthens international demand, setting the stage for future growth. |
Ekso Bionics (EKSO) Reports Q3 Loss, Misses Revenue EstimatesEkso Bionics (EKSO) delivered earnings and revenue surprises of -25% and 31.21%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Ekso Bionics: Q3 Earnings SnapshotSAN RAFAEL, Calif. AP) — Ekso Bionics Holdings Inc. EKSO) on Monday reported a loss of $2.1 million in its third quarter. |
Ekso Bionics Announces Third Quarter 2024 Financial ResultsSAN RAFAEL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2024. Recent Highlights and Accomplishments Reported revenue of $4.1 million in the third quarter of 2024Sold a total of 33 EksoHealth devices in the third quarter of 2024Announced receipt of initial Centers for Medicare & Med |
Ekso Bionics to Report Third Quarter 2024 Financial Results on October 28, 2024SAN RAFAEL, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2024 after the close of trading on Monday, October 28, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live webc |
Ekso Bionics Announces Pricing of $6.0 Million Underwritten Public OfferingSAN RAFAEL, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced the pricing of an underwritten public offering of 6,000,000 total units and pre-funded units for gross proceeds of approximately $6.0 million prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of 3,100,000 units, priced |